Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021


HomeEXECUTIVESVectivBio Announces New Appointments

VectivBio Announces New Appointments

November 4, 2020

VectivBio has announced the appointment of Sarah Holland, Ph.D., as Chief Business Officer and Aditya Venugopal, Ph.D., as Vice President of Business Development. Dr. Holland will be based in Switzerland and Dr. Venugopal will be based in the U.S., further expanding the company’s global reach.

VectivBio. Chief Executive Officer Luca Santarelli, MD said, “We are truly fortunate to have Sarah and Aditya on our team. Their complementary expertise will enhance our ability to expand our pipeline as we continue to build our company to become a global rare disease leader. Sarah’s impressive track record of dealmaking speaks to her incredible leadership and drive, essential for this role, while Aditya is highly skilled in search and evaluation.”

Dr. Holland has a strong track record of leadership. Most recently, she served as Global Head of licensing at Lonza AG where she built the new licensing business unit, led research and development and drove the spin-off of Affinia Therapeutics. Prior to Lonza, she led External Science and Partnering across the globe for Sanofi R&D.

Before that, Dr. Holland served at Roche for over a decade in positions of increasing responsibility, culminating as Life Cycle Leader for ALECENSA® (alectinib). She led many deals for Roche Partnering, including licensing ZELBORAF® (vemurafenib) from Plexxikon and establishing a key CNS partnership with PTC Therapeutics. She built the team responsible for championing and integrating company acquisitions and drove the Roche strategy for rare diseases. Dr. Holland earned an M.A. and D.Phil. in chemistry from the University of Oxford and an MBA from Manchester Business School.

“I was drawn to VectivBio because of its impressive team with a proven track record of value creation,” said Dr. Holland. “In particular, I appreciated the team’s rigorous, well-designed development strategies and success in securing funding for their plans. I am eager to work with the VectivBio team to create a leading portfolio in rare diseases with high unmet need. I look forward to engaging with innovators and investors to explore new pipeline opportunities.”

Dr. Venugopal was most recently an Executive Director at Intercept Pharmaceuticals, where he held roles leading corporate strategic planning and business development (BD). While at Intercept, he drove BD expansion efforts in hepatology and gastroenterology. Previously, he was an Associate Director at Navigant Life Science Consulting where he led global cross-functional teams focused on business development and licensing assessments in immunology, oncology and rare diseases. Dr. Venugopal earned a Ph.D. in immunology and microbiology from Cornell University Medical College and a B.E. in biotechnology from Anna University in India.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy